Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review.

Antimicrobial agents and chemotherapy·2026

Same author

Early Signal Without Clinical Cases: A Single Clade III <i>Candidozyma auris</i> Isolate from a Face Mask Highlights the Value of Environmental Quality Control.

Journal of fungi (Basel, Switzerland)·2026

Same author

Can voriconazole gradient diffusion testing results be extrapolated to isavuconazole and posaconazole in <i>Aspergillus</i> spp.? Comparative analysis with CLSI broth microdilution and <i>cyp51A</i> gene sequencing.

Antimicrobial agents and chemotherapy·2026

Same author

An automated workflow for fungal cell counting, cell size and data analysis: enhancing throughput and accuracy with the cell analysis and counting tool using ilastik software (caactus).

BMC microbiology·2026

Same author

Six-month surveillance of <i>Candida parapsilosis</i> in Tyrol, Austria: high-risk ST11 lineage and early, heterogeneous fluconazole resistance.

Frontiers in cellular and infection microbiology·2026

Same author

Closing the gap on antifungal resistance.

Nature medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

EUCAST breakpoints for antifungals.

Juan L Rodríguez-Tudela¹, Maiken C Arendrup, Manuel Cuenca-Estrella

¹Micology Service, National Microbiology Center, Carlos III Health Institute, Madrid, Spain. jlrtudela@isciii.es

Drug News & Perspectives

|April 7, 2010

Summary

The European Committee on Antibiotic Susceptibility Testing (EUCAST) outlines its method for establishing antifungal susceptibility testing breakpoints. This process ensures accurate interpretation of antifungal resistance in clinical settings.

More Related Videos

Passaging HuES Human Embryonic Stem Cell-lines with Trypsin.

Passaging HuES Human Embryonic Stem Cell-lines with Trypsin.

Published on: October 12, 2006

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Experiment Videos

Last Updated: Jun 14, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Passaging HuES Human Embryonic Stem Cell-lines with Trypsin.

Passaging HuES Human Embryonic Stem Cell-lines with Trypsin.

Published on: October 12, 2006

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Area of Science:

Medical Mycology
Clinical Microbiology
Pharmacology

Background:

Invasive fungal infections are increasing, alongside the development of new antifungals and reports of resistance.
Accurate antifungal susceptibility testing and interpretative breakpoints are crucial for effective treatment.

Purpose of the Study:

To describe the European Committee on Antibiotic Susceptibility Testing (EUCAST) process for setting antifungal breakpoints.
To detail the methodology used by EUCAST in developing standards for antifungal susceptibility testing.

Main Methods:

Evaluation of common European drug dosages.
Definition of wild-type microbial populations and epidemiological cutoffs.
Analysis of drug pharmacokinetics, pharmacodynamics (including Monte Carlo simulations), and MIC-clinical outcome correlations.

Main Results:

EUCAST has developed standards for yeast and mold susceptibility testing.
Proposed breakpoints for fluconazole and voriconazole against Candida species have been established.
Epidemiological cutoff values are recommended when clinical outcome data are insufficient for breakpoint determination.

Conclusions:

The EUCAST breakpoint setting process is a comprehensive evaluation of multiple factors.
This systematic approach aims to improve the clinical utility of antifungal susceptibility testing.
The process ensures that breakpoints are based on robust scientific evidence and clinical relevance.